A phase1 study to evaluate the long toxicology and pharmacological dosing of T20K
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs T-20K (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man
- 23 Oct 2018 According to a Cyxone media release, the company has selected the clinical site located in Western Europe and has been carefully evaluated based on a number of crucial criteria. The company is preparing to submit an application to start clinical studies.
- 14 May 2018 New trial record
- 10 May 2018 According to a Cyxone media release, the company is planning to initiate this study in 2018.